These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 31588803

  • 1. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 2. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 3. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr 28; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 4. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 28; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
    Kim JY, Jayne LA, Bai Y, Feng MJHH, Clark MA, Chung S, W Christman J, Cianciolo RE, Pabla NS.
    Biochem Pharmacol; 2020 Jul 28; 177():113939. PubMed ID: 32229099
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
    Ji J, Zhang Z, He X, Pan G, Li G, Lv J, Xu Y, Xie M, Feng J, Wang W, Liu B, Ma J, Wang X.
    Anticancer Drugs; 2023 Aug 01; 34(7):803-815. PubMed ID: 36729405
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
    Scheinberg T, Kench J, Stockler M, Mahon KL, Sebastian L, Stricker P, Joshua AM, Woo H, Thanigasalam R, Ahmadi N, Centenera MM, Butler LM, Horvath LG.
    BMJ Open; 2020 Jan 26; 10(1):e033667. PubMed ID: 31988233
    [Abstract] [Full Text] [Related]

  • 12. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G, Schmitz S, El Baroudi M, Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D, Machiels JP.
    Mol Cancer Ther; 2020 Mar 26; 19(3):777-789. PubMed ID: 31924739
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D, Bardia A, Sellers WR.
    Clin Cancer Res; 2017 Jul 01; 23(13):3251-3262. PubMed ID: 28351928
    [Abstract] [Full Text] [Related]

  • 19. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D.
    Breast Cancer Res Treat; 2017 Nov 01; 166(1):41-54. PubMed ID: 28741274
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.